Sirona Biochem Corp.
TSX VENTURE : SBM

Sirona Biochem Corp.

April 19, 2011 09:25 ET

Sirona Biochem Appoints Dermatology Expert Dr. Stuart Maddin to Scientific Advisory Board

VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 19, 2011) -Sirona Biochem Corp. (TSX VENTURE:SBM) (the "Company"), a biotechnology company specializing in carbohydrate chemistry technology, including diabetes and obesity therapeutics, cosmeceuticals and biological ingredients, is pleased to announce today the appointment of internationally renowned dermatology expert, Dr. Stuart Maddin, to its Scientific Advisory Board.

"Dr. Stuart Maddin's valuable insight on dermatological advances will help ensure Sirona Biochem's development programs are focused on high value cosmeceuticals," said Sirona Biochem's President Mark Senner. "Sirona Biochem's proprietary carbohydrate technology has the potential for the development of new cosmeceutical products and Dr. Maddin's strong network in the dermatology field will assist us in identifying potential partners," he added.

"Sirona Biochem has an opportunity to develop new anti-aging cosmetic agents in this growing cosmetic industry," said Dr. Stuart Maddin. "There is a tremendous demand for anti-aging products and Sirona Biochem's technology is showing promise to deliver on these unmet needs," Dr. Maddin added.

On March 31, 2011, Sirona Biochem acquired TFChem. With the newly acquired carbohydrate chemistry platform, Sirona Biochem plans to develop three major programs – diabetes and obesity therapeutics, anti-aging cosmeceuticals and biological ingredients. The Company has identified cosmeceuticals and biological ingredients as high valued programs with lower development costs and shorter development timelines.

Biography of Dr. Stuart Maddin

Dr. Stuart Maddin is Clinical Professor Emeritus at the Department of Dermatology and Skin Science of Dermatology (Active), Faculty of Medicine, University of British Columbia, where he is the Director of the Clinical Trials Unit.

Dr. Maddin has served in an advisory capacity to the Health Protection Branch (Ottawa), U.S. Pharmacopeial Convention (Rockville, MD), Essential Drugs for the World Health Organization (W.H.O. in Geneva) as well as AAD – Therapeutics / FDA Liaison Task Force. Dr. Maddin has also served as a member of the Board of Directors of the American Academy of Dermatology, Secretary and President of the Canadian Dermatology Association and also as Vice President of the American Dermatology Association. He was the first Canadian to be elected to the International Committee of Dermatology (ICD) and was later appointed as Secretary-General of the ICD (International League of Dermatologic Societies). Dr. Maddin is a founding member of the Regional Dermatology Training Centre in Moshi, Tanzania.

At present, Dr. Maddin is the Editor-in-Chief of Skin Therapy Letter, now in its 16th year of publication (indexed by the National Library of Medicine and viewable at www.SkinInformation.com). Dr. Maddin is co-founder and chairman of the SkinInformation.com network of dermatology-related websites, which provides comprehensive information to patients and physicians. He has authored over 60 articles in the field of dermatology.

Dr. Maddin is also the founder and director of the Dermatology Update Symposium which is now in its 27th year.

About Sirona Biochem Corp.

Sirona Biochem is a biotechnology company developing diabetes and obesity therapeutics, cosmeceuticals and biological ingredients. We are applying a proprietary chemistry technique to improve the pharmaceutical properties of our carbohydrate-based molecules. Our lead product, a sodium glucose transporter (SGLT) inhibitor for Type 2 diabetes, recently achieved positive preclinical results. For more information visit www.sironabiochem.com.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information